Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts on July 25, 2016. The debtor listed its assets in the range of $0.67 million and liabilities of $10.36 million. The debtor is represented by Daniel S. Bleck of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as its legal counsel. Mark G. DeGiacomo has been appointed as the case trustee.